Liposomes in Drug Delivery
What, Where, How and When to deliver
- 1st Edition - April 10, 2024
- Editor: Sophia G. Antimisiaris
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 1 5 4 9 1 - 1
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 5 4 9 2 - 8
Liposomes in Drug Delivery: What, Where, How and When to Deliver is a concise, well-structured reference covering all the important issues related to the potential of this tech… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteLiposomes in Drug Delivery: What, Where, How and When to Deliver is a concise, well-structured reference covering all the important issues related to the potential of this technology. Organized to provide practical information to researchers from any discipline with a particular therapeutic or bio-active substance to deliver, this book helps readers understand if liposomes can be of benefit for their particular need, what is the best type of liposome to use according to what needs to be delivered, where/when to deliver it, and how to design/prepare/characterize/investigate/optimize liposome properties for a particular application.
The book is structured in Four parts. The first covers in a concise but in-depth way, what liposomes are, which are the liposome types, advantages/disadvantages, and what is their stability, characterization methods, in vitro stability, and in vivo fate after different administration methods (routes). The second part focuses on the different mechanisms for liposomal drug delivery. Methodologies/technologies for manipulation of liposome structure/properties in order to design liposomes for particular delivery applications. Specific roadmaps for liposome design are discussed, including components to incorporate in liposomes for specific types of encapsulated molecules or specific routes of administration. The third part covers liposome applications for drug delivery. It focuses on specific delivery considerations for particular diseases. Finally, the fourth part covers methods of liposome fabrication.
- Focuses on key information - What, Where, How and When to deliver – needed for drug delivery researchers
- Covers all aspects of liposomes in drug delivery in one single volume
- Guides researchers through the decision process on whether and what liposomes are most applicable to their particular interest
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Foreword
- Preface
- Acknowledgments
- Chapter 1. Introduction to liposome assisted drug delivery
- 1.1. Introduction
- 1.2. What are liposomes? A trip through liposome evolution
- 1.3. What types of drugs or active substances can liposomes deliver?
- 1.4. Where can liposomes deliver drugs to?
- 1.5. How can liposomes deliver the drugs/active substances to the intended sites?
- 1.6. How are liposomes prepared/loaded with drugs and characterized?
- 1.7. When is delivery of drugs/active substances via liposomal formulations useful?
- 1.8. Summary
- Chapter 2. Basic concepts of liposomes: Components, structures, properties and classification
- 2.1. Introduction
- 2.2. Liposome components, structure, and properties
- 2.3. Classifications of liposomes
- Chapter 3. Liposome characterization methodologies (physical and chemical methods)
- 3.1. Introduction
- 3.2. Methods applied for size distribution
- 3.3. Surface charge/properties
- 3.4. Drug release, integrity, and stability
- 3.5. Osmolarity and pH
- 3.6. Summary
- Chapter 4. Morphological assessment of liposomes by microscopy
- 4.1. Introduction
- 4.2. Negative staining
- 4.3. Freeze fracture electron microscopy
- 4.4. Light microscopy
- 4.5. Dynamic light scattering
- 4.6. Small angle X-ray scattering
- 4.7. Fluorescent spectroscopy
- 4.8. Atomic force microscopy
- 4.9. Cryo-electron microscopy
- 4.10. Liposomal characterizations in drug delivery
- 4.11. Conclusion
- Chapter 5. Liposome stability and integrity
- 5.1. Introduction
- 5.2. Insights on the membrane fluidity of liposomes
- 5.3. Intrinsic/external factors affecting membrane fluidity and liposomes stability
- 5.4. Methods to assess membrane fluidity
- 5.5. Membrane integrity and methods to assess it
- 5.6. Physical stability of liposomes: factors implicated in colloidal stability and novel stabilization strategies
- 5.7. Chemical stability of liposomes and stabilization approaches
- 5.8. Liposome-based mRNA vaccines for COVID-19
- 5.9. Summary
- Chapter 6. In vivo fate of liposomes: Biodistribution and cell membrane interactions
- 6.1. Introduction
- 6.2. Pharmacokinetics of liposomes
- 6.3. Absorption of liposomal formulations via various routes of administration
- 6.4. Distribution of liposomes
- 6.5. Clearance of liposomes from the systemic circulation
- 6.6. In vivo behavior of liposomes
- 6.7. Factors affecting the liposomal pharmacokinetic behavior
- 6.8. The bottleneck for translation into clinical practice
- 6.9. Summary and conclusions
- Acknowledgments
- Chapter 7. Liposomes in controlled drug delivery: Controlling drug release kinetics and biodistribution/pharmacokinetics
- 7.1. Introduction
- 7.2. Release of drugs/active substances from liposomes and factors affecting drug release
- 7.3. Controlling the release of drugs/active substances from liposomes
- 7.4. Controlling the time and place where the drug will be released: Targeting
- 7.5. Smart delivery: Stimuli-responsive liposomes
- 7.6. Successful and unfinished stories
- 7.7. Promises
- Chapter 8. Liposome surface modifications-engineering techniques
- 8.1. Introduction
- 8.2. Importance and advantage of polymer coating for liposomes
- 8.3. Engineering techniques for coupling ligands
- 8.4. Innate immunity activation
- 8.5. Alternative method to PEG coating using phospholipid polymer derivatives
- 8.6. Future perspective
- Chapter 9. Activatable liposomes: Ultrasound-activated liposomes and lipid vesicles
- 9.1. Introduction: Nanoparticles advanced in the clinic for cancer treatment
- 9.2. Fundamentals of tissue penetrating focused ultrasound
- 9.3. Focused ultrasound causing thermal activated liposome drug release in tumors
- 9.4. Activatable liposomes as theranostic agents
- 9.5. Cavitation activatable gas containing lipid vesicles as theranostics agents
- 9.6. Conclusions
- Chapter 10. Liposomes for drug delivery to the brain
- 10.1. Introduction
- 10.2. Methods of transport across BBB
- 10.3. Direct nose-to-brain route
- 10.4. Advancements in liposome-based approaches for brain targeting
- 10.5. Liposomes as diagnostic tools
- 10.6. Current challenges and future perspectives
- Chapter 11. Liposomes for drug delivery to cancer cells
- 11.1. Introduction
- 11.2. Agents delivered by liposomes and liposome delivery properties
- 11.3. Delivery targets and first steps toward dosimetry-informed personalized treatments
- 11.4. Routes of administration
- 11.5. Chapter review
- Chapter 12. Liposomes as vaccine delivery systems
- 12.1. Introduction on liposomes used as a vaccine adjuvant-delivery systems
- 12.2. Liposomes used for delivering mRNA vaccines
- 12.3. Liposome-delivered subunit vaccines
- 12.4. Challenges and perspectives on liposome VADS
- Chapter 13. Liposomes as DNA, mRNA and oligonucleotide delivery vectors
- 13.1. Introduction to nucleic acids delivery
- 13.2. Cationic liposomes
- 13.3. Conclusions and future perspective
- Chapter 14. Liposomes for drug delivery by localized routes of administration
- 14.1. Introduction
- 14.2. Lung delivery
- 14.3. Intra-articular delivery
- 14.4. Ocular delivery
- 14.5. Vaginal delivery
- 14.6. Dermal delivery
- 14.7. Nasal delivery
- 14.8. Periodontal delivery
- 14.9. Intratumoral administration
- 14.10. Summary
- Chapter 15. Liposomes for infectious diseases
- 15.1. Introduction-infectious diseases. Definition, categories and general treatment options
- 15.2. Strategies/mechanisms of liposome applications to treat infectious diseases
- 15.3. Liposomes for treatment of bacterial infections
- 15.4. Liposomes against fungal infections
- 15.5. Liposomes against virus infections
- 15.6. Liposomes against parasite infections
- 15.7. Clinical trials and products of liposomes for treatment of IDs
- Chapter 16. Liposomes for drug delivery via biomaterials
- 16.1. Introduction
- 16.2. Liposomes and bone scaffolds
- 16.3. Liposomes and drug—Eluting stents
- 16.4. Liposomes and implants for treatment of infections
- 16.5. Liposomes integrated in implants for antitumor therapy
- 16.6. Liposomes integrated in implants for wound healing/dressing
- 16.7. Clinical studies
- 16.8. Summary
- Chapter 17. Liposomes for delivery of substances for other (non-therapeutic) applications
- 17.1. Liposomes for non-therapeutic applications introduction
- 17.2. Concluding remarks
- Chapter 18. Conventional methods for preparing liposomes of various types (MLVs, LUVs, SUVs): What, where, how and when
- 18.1. Introduction
- 18.2. Mechanism of liposome formation
- 18.3. Passive and active drug loading approaches
- 18.4. General drug loading approaches
- 18.5. Conventional methods for the preparation of phospholipid vesicles
- 18.6. Conclusions
- Chapter 19. Size reduction, purification, sterilization and storage/packaging of liposomes
- 19.1. Introduction
- 19.2. Liposome sizing
- 19.3. Liposome purification
- 19.4. Sterilization
- 19.5. Packaging and storage
- 19.6. Summary
- Chapter 20. Methods for preparation of giant liposomes: Conventional methods; modified electro-techniques
- 20.1. Introduction
- 20.2. Method of preparation of giant liposomes
- 20.3. Morphological modulation in giant liposomes
- 20.4. Potential of the above discussed methods to comply with regulatory guidelines for liposome products
- 20.5. Applications of giant liposomes in drug delivery
- 20.6. Conclusion and future direction
- Chapter 21. Microfluidic methods for liposome formation
- 21.1. Introduction
- 21.2. Microfluidic mixing
- 21.3. Microfluidic preparation of liposomes
- 21.4. Microfluidic for advancing clinical applications
- 21.5. Concluding remarks
- Chapter 22. Supercritical fluid methods for liposome production and sterilization
- 22.1. Introduction
- 22.2. Theoretical basis of methods
- 22.3. Supercritical fluids to produce liposomes
- 22.4. Supercritical fluids for the sterilization of liposomes
- 22.5. Supercritical fluids for the production and the sterilization of liposomes in a one step process
- 22.6. Potential of the method to comply with regulations guidelines for liposome products
- 22.7. Comparison to other novel methods
- 22.8. Conclusion
- Chapter 23. Design of experiment approaches for liposome property optimization
- 23.1. Introduction
- 23.2. Definitions
- 23.3. The critical quality attributes (CQAs)
- 23.4. The critical material attributes (CMAs)
- 23.5. The critical process parameters (CPPs)
- 23.6. Application of DoE in liposome development
- 23.7. Factorial and fractional factorial designs
- 23.8. Box-Behnken design
- 23.9. Plackett Burman design
- 23.10. Central composite design
- 23.11. Response surface methodology (RSM)
- 23.12. Taguchi design
- 23.13. Challenges and future perspectives
- 23.14. Conclusions
- Chapter 24. Development of generic liposome products for drug delivery
- 24.1. Introduction
- 24.2. Development of generic liposome formulation
- 24.3. Regulatory considerations for liposomal products
- 24.4. General considerations for the design of a liposomal formulation
- 24.5. Manufacturing process
- 24.6. Methods of drug loading
- 24.7. Processing of developed liposomes
- 24.8. Testing/analysis of liposomal formulations
- 24.9. Conclusion
- Chapter 25. Success stories, final remarks and directions of the field
- 25.1. Conclusions – the current state of liposomes for drug delivery
- 25.2. Remaining challenges and future perspectives
- 25.3. Summary
- Index
- No. of pages: 696
- Language: English
- Edition: 1
- Published: April 10, 2024
- Imprint: Academic Press
- Paperback ISBN: 9780443154911
- eBook ISBN: 9780443154928
SA
Sophia G. Antimisiaris
Professor Antimisiaris’ lab has extensive experience (more than 25 years) in design and production of liposomal and lipid/polymer/cyclodextrin hybrid nanoparticulates for drug and/or imaging agent delivery and targeting to specific target cells. Several administration routes have been investigated or are under investigation in regards to the specific requirements of liposomes for each specific route (such as: iv, ip, oral, lung/intrapleural, ocular/intravitreal, vaginal, etc.). Her laboratory also has long term collaborations with industries and is involved in development of new products. She has experience as coordinator and/or WP-leader in several large scale European Collaborative Projects, as Shiva (FP6), for development of liposomal microbicides for vaginal delivery, NAD (FP7, Nanoparticles for diagnosis and Therapy of AD), for design and development of liposomes s with affinity for Abeta peptides, SBR (Smart Bone Regeneration, H2020), for development of liposomal growth factors integrated in biomaterials. Her team have also been working for many years on the application of arsonolipid-containing liposomes for therapy of cancer with promising in vitro and in vivo results. They also investigate the development of novel platforms for sustained release of drugs following ocular/intravitreous, vaginal, intrapleural or subcutaneous administration.